Last reviewed · How we verify

Acusphere — Portfolio Competitive Intelligence Brief

Acusphere pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
AI-700 AI-700 phase 3 Ultrasound contrast agent Diagnostic Imaging

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bracco Diagnostics, Inc · 1 shared drug class
  2. Centre Hospitalier Régional Metz-Thionville · 1 shared drug class
  3. Children's Hospital of Philadelphia · 1 shared drug class
  4. GE Healthcare · 1 shared drug class
  5. Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 shared drug class
  6. Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 1 shared drug class
  7. Sunnybrook Health Sciences Centre · 1 shared drug class
  8. UNC Lineberger Comprehensive Cancer Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Acusphere:

Cite this brief

Drug Landscape (2026). Acusphere — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acusphere. Accessed 2026-05-14.

Related